On April 28, 2026, BioLineRx Ltd. (NASDAQ: BLRX) and partner Hemispherian AS announced that the first patient was dosed in their Phase 1/2a study of GLIX1, a first‑in‑class oral DNA damage response inhibitor for recurrent and progressive glioblastoma and other high‑grade gliomas.
GLIX1 was administered at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro‑Oncology at the Perlmutter Cancer Center. Data collection for the Phase 1 portion of the study is expected to begin in the first half of 2027.
The GLIX1 program is a key development for BioLineRx, targeting a $3.7 billion glioblastoma market. The partnership, announced in September 2025, is structured as a joint venture in which Hemispherian initially holds 60% of the shares and BioLineRx 40%, with the possibility of increasing BioLineRx’s stake to 70% through additional investment. BioLineRx will manage, fund, and conduct all development activities.
"The dosing of the first patient in our Phase 1/2a study of GLIX1 is an important milestone for BioLineRx and, more importantly, for patients battling glioblastoma, a very challenging tumor where there has been very little innovation over the past 20 years," said Philip Serlin, CEO of BioLineRx. "We believe GLIX1 has the potential to offer a novel therapeutic approach in this cancer indication, as well as in multiple other cancer indications, where DNA damage repair is critical for cancer survival. We are excited to advance GLIX1 development into this first‑in‑human clinical trial and look forward to initial data in the first half of 2027." Zeno Albisser, CEO of Hemispherian, added, "The initiation of patient dosing in this important study represents a watershed event for Hemispherian and GLIX1." Adam Robertson, Chief Scientific Officer at Hemispherian, remarked, "GLIX1 is built on a fundamentally new understanding of how to exploit DNA repair vulnerabilities in cancer. The strength and consistency of the preclinical data give us confidence as we now transition this mechanism into the clinic."
BioLineRx’s financial context underscores the strategic importance of the GLIX1 milestone. In Q1 2025 the company reported $0.3 million in revenue, down from $6.9 million in Q1 2024, but posted a net income of $5.1 million versus $0.7 million in the prior year, reflecting a shift away from its U.S. commercial operations and the out‑licensing of its product Aphexda. As of December 31 2025, BioLineRx held $20.9 million in cash, a runway that is expected to support operations through the first half of 2027.
Regulatory milestones support the clinical progress: an IND for GLIX1 was cleared by the FDA in August 2025, and the drug received orphan drug designation from both the FDA and EMA. The Phase 2a expansion of the trial is planned to include additional indications, including newly diagnosed glioblastoma and other cancers, with potential combination strategies involving standard of care or PARP inhibitors.
The first patient dosing marks a critical step toward potential regulatory approval and future revenue generation for BioLineRx, positioning the company to address an unmet need in a sizable glioblastoma market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.